IM
IMU.AU Imugene Ltd
- Market cap
- AUD 19.4M
- P/E
- -
- P/B
- 2.15x
- ROE
- -1,169.2%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IMU.AU undervalued?
Graham numberThe Graham number of Imugene Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Imugene Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-1,169.2%), below 10%.
ROA 0/1
Return on assets (-457.4%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (-2.4%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (69.9%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (2.2x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Imugene Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to gener…
Full company profileImugene Ltd financial statements
Imugene Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.16M | 1.84M | 4.13M | 4.13M | 7.23M | 13.0M | 11.8M | 4.97M | 4.40M | - |
| Gross Profit | 1.16M | 1.84M | 4.06M | 4.05M | 5.27M | 10.6M | 9.57M | 4.97M | 4.40M | -6.84M |
| Operating Income | -3.69M | -5.78M | -12.4M | -10.8M | -25.7M | -50.7M | -51.3M | -141M | -70.9M | -75.0M |
| EBITDA | -3.67M | -5.77M | -7.71M | -14.6M | -23.7M | -48.1M | -47.4M | -148M | -66.7M | -68.1M |
| Net Income | -2.51M | -3.93M | -7.78M | -10.5M | -18.5M | -37.9M | -37.9M | -150M | -69.0M | -105M |
| EPS | -0.04 | -0.05 | 0.00 | -0.09 | -0.13 | -0.23 | -0.01 | -0.72 | -0.32 | -0.32 |
| Balance Sheet | ||||||||||
| Total Assets | 12.7M | 16.9M | 30.8M | 65.2M | 71.8M | 148M | 197M | 151M | 83.6M | 23.0M |
| Total Liabilities | 1.28M | 1.44M | 3.48M | 5.40M | 6.79M | 8.90M | 7.44M | 33.1M | 38.6M | 14.0M |
| Shareholders' Equity | 11.4M | 15.5M | 27.3M | 59.8M | 65.0M | 139M | 190M | 118M | 45.0M | 9.01M |
| Cash & Short-term Investments | 4.81M | 7.82M | 19.0M | 30.1M | 29.5M | 99.9M | 153M | 94.5M | 21.9M | 2.63M |
| Total Debt | - | - | 1.11M | 69.3K | 271K | 673K | 553K | 2.19M | 10.7M | 6.30M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.67M | -4.51M | -7.91M | -10.1M | -13.1M | -30.7M | -29.8M | -102M | -75.6M | -44.9M |
| Capital Expenditure | 2.03K | 3.33K | 128K | 1.49M | 5.45M | 258K | 0.00 | 7.07M | 14.5M | 5.00 |
| Free Cash Flow | -2.68M | -4.51M | -8.04M | -11.6M | -18.6M | -30.9M | -29.8M | -109M | -90.0M | -44.9M |
| Ratios | ||||||||||
| ROE | -22.0% | -25.4% | -28.5% | -17.6% | -28.4% | -27.3% | -20.0% | -126.6% | -153.3% | -1,169.2% |
| ROA | -19.8% | -23.3% | -25.3% | -16.1% | -25.7% | -25.7% | -19.2% | -98.9% | -82.6% | -457.4% |
| Net Profit Margin | -215.4% | -213.7% | -188.4% | -254.2% | -255.2% | -292.0% | -321.9% | -3,011.7% | -1,569.8% | - |
| Debt to Equity | - | - | 0.04x | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x | 0.24x | 0.70x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Imugene Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 77.9M | 0.01 | - |
| 2022 | AUD 6.01M | 0.04 | - |
| 2021 | AUD 17.9M | 0.13 | - |
| 2020 | AUD 20.9M | 0.17 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:34 on Jul 2, 2025.
Who owns Imugene Ltd
- Insiders 9.30%
- Institutions 9.51%
- Public & others 81.19%
- Shares outstanding 554M
- Free float 438M
Top funds holding IMU.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| DFA International Sustainability Core 1 Portfolio | 1.29M | 0.03% | - | Jan 2021 |
Imugene Ltd company profile
- Company name
- Imugene Ltd
- Ticker
- IMU.AU
- ISIN
- AU000000IMU9
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- June
- Address
- 4-6 Bligh Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 9423 0881
- Website
- imugene.com
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and Neo-POLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
Imugene Ltd management
1- Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICDExecutive Chairman · born 1956